Evidence map›Paper›PMID 36050781›Full record

ReviewArchives of public health = Archives belges de sante publique2022

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review.

Isaac Yeboah Addo, Frederick Asankom Dadzie, Sylvester Reuben Okeke, Caleb Boadi, Elijah Frimpong Boadu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of public health = Archives belges de sante publique, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Isaac Yeboah AddoCentre for Social Research in Health, University of New South Wales, Sydney, 2052, Australia. i.addo@unsw.edu.au.ORCID http://orcid.org/0000-0001-8603-8306
Frederick Asankom DadzieCentre for Ecosystem Science, School of Biological, Earth and Environmental Sciences, University of New South Wales, Sydney, 2052, Australia.
Sylvester Reuben OkekeCentre for Social Research in Health, University of New South Wales, Sydney, 2052, Australia.
Caleb BoadiDepartment of Operations and Management Information Systems, University of Ghana, Accra, Ghana.
Elijah Frimpong BoaduSchool of Built Environment, University of New South Wales, Sydney, 2052, Australia.
UNSW Sydney · AUUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs vaccine roll-out continues across the globe as part of the efforts to protect humanity against SARS-CoV-2, concerns are increasingly shifting to the duration of vaccine-induced immunity. Responses to these concerns are critical in determining if, when, and who will need booster doses following full vaccination against SARS-CoV-2. However, synthesised studies about the durability of vaccine-induced immunity against SARS-CoV-2 are scarce. This systematic review synthesised available global evidence on the duration of immunity following full vaccination against SARS-CoV-2.

methodsWe searched through Psych Info, Web of Science, Scopus, Google Scholar, PubMed, and WHO COVID-19 databases for relevant studies published before December 2021. Five eligibility criteria were used in scrutinising studies for inclusion. The quality of the included studies was assessed based on Joana Briggs Institute's (JBI) Critical Appraisal tool and Cochrane's Risk of Bias tool-version 2 (RoB 2), while the reporting of the results was guided by the Synthesis Without Meta-analysis (SWiM) guidelines.

resultsTwenty-seven out of the 666 identified studies met the inclusion criteria. The findings showed that vaccine-induced protection against SARS-CoV-2 infections builds rapidly after the first dose of vaccines and peaks within 4 to 42 days after the second dose, before waning begins in subsequent months, typically from 3 to 24 weeks. Vaccine-induced antibody response levels varied across different demographic and population characteristics and were higher in people who reported no underlying health conditions compared to those with immunosuppressed conditions.

conclusionsWaning of immunity against SARS-CoV-2 begins as early as the first month after full vaccination and this decline continues till the sixth month when the level of immunity may not be able to provide adequate protection against SARS-CoV-2. While the evidence synthesised in this review could effectively inform and shape vaccine policies regarding the administration of booster doses, more evidence, especially clinical trials, are still needed to ascertain, with greater precision, the exact duration of immunity offered by different vaccine types, across diverse population characteristics, and in different vulnerability parameters. REGISTRATION: The protocol for this review was pre-registered with the International Prospective Register of Systematic Reviews [PROSPERO] (Registration ID: CRD420212818).

Indexed as

BoosterCOVID-19 vaccinesEquityImmunityOmicronSARS-CoV-2Waning

Identifiers

PMID36050781
PMCPMC9436729
OpenAlexW4294152314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.